肾透明细胞癌中炎症反应指数的临床意义及其在免疫治疗中的应用进展
The Clinical Significance of the Inflammatory Response Index in Clear Cell Renal Cell Carcinoma and Its Application Progress in Immunotherapy
DOI: 10.12677/acm.2026.161119, PDF,    科研立项经费支持
作者: 瞿筠泷：绍兴文理学院医学院，浙江 绍兴；绍兴市人民医院暨绍兴文理学院附属第一医院泌尿外科，浙江 绍兴；李俊龙*：绍兴市人民医院暨绍兴文理学院附属第一医院泌尿外科，浙江 绍兴
关键词: 肾透明细胞癌；炎症反应指数；免疫治疗；生物标志物；肿瘤微环境；Clear Cell Renal Cell Carcinoma (ccRCC)； Inflammatory Response Index (IRI)； Immunotherapy； Biomarker； Tumor Microenvironment (TME)
摘要: 肾透明细胞癌(ccRCC)是肾癌中最常见的亚型，其发生发展与炎症微环境密切相关。炎症反应指数(IRI)作为一种新兴的生物标志物，在ccRCC的临床诊治和预后评估中显示出重要价值。近年来，随着免疫治疗的快速发展，IRI在预测ccRCC患者对免疫治疗反应方面的潜力逐渐受到关注。研究表明，IRI不仅能够反映肿瘤微环境的炎症状态，还与免疫检查点抑制剂的疗效密切相关。然而，目前关于IRI在ccRCC中的具体作用机制及其临床应用标准仍存在诸多争议。本文综述了IRI在ccRCC中的生物学机制、临床应用及其与免疫治疗的协同作用，旨在为优化ccRCC的个体化治疗策略提供理论依据，并探讨未来研究的方向和挑战。
Abstract: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma, and its occurrence and progression are closely associated with the inflammatory microenvironment. As an emerging biomarker, the Inflammatory Response Index (IRI) has shown significant value in the clinical diagnosis, treatment, and prognostic evaluation of ccRCC. In recent years, with the rapid advancement of immunotherapy, the potential of IRI in predicting the response of ccRCC patients to immunotherapy has garnered increasing attention. Studies have demonstrated that IRI not only reflects the inflammatory status of the tumor microenvironment but also exhibits a close correlation with the efficacy of immune checkpoint inhibitors. However, numerous controversies remain regarding the specific mechanisms of action of IRI in ccRCC and its clinical application standards. This review summarizes the biological mechanisms, clinical applications of IRI in ccRCC, as well as its synergistic effects with immunotherapy, aiming to provide a theoretical basis for optimizing individualized treatment strategies for ccRCC and exploring the directions and challenges of future research.
文章引用：瞿筠泷, 李俊龙. 肾透明细胞癌中炎症反应指数的临床意义及其在免疫治疗中的应用进展[J]. 临床医学进展, 2026, 16(1): 904-911. https://doi.org/10.12677/acm.2026.161119

参考文献

[1] Hsieh, J.J., Purdue, M.P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., et al. (2017) Renal Cell Carcinoma. Nature Reviews Disease Primers, 3, Article No. 17009. [Google Scholar] [CrossRef] [PubMed]
[2] Moch, H., Amin, M.B., Berney, D.M., Compérat, E.M., Gill, A.J., Hartmann, A., et al. (2022) The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. European Urology, 82, 458-468. [Google Scholar] [CrossRef] [PubMed]
[3] Şenbabaoğlu, Y., Gejman, R.S., Winer, A.G., Liu, M., Van Allen, E.M., de Velasco, G., et al. (2016) Tumor Immune Microenvironment Characterization in Clear Cell Renal Cell Carcinoma Identifies Prognostic and Immunotherapeutically Relevant Messenger RNA Signatures. Genome Biology, 17, Article No. 231. [Google Scholar] [CrossRef] [PubMed]
[4] Zuo, R., Zhu, F., Zhang, C., Ma, J., Chen, J., Yue, P., et al. (2023) The Response Prediction and Prognostic Values of Systemic Inflammation Response Index in Patients with Advanced Lung Adenocarcinoma. Thoracic Cancer, 14, 1500-1511. [Google Scholar] [CrossRef] [PubMed]
[5] Ma, W., Liu, R., Li, X., Yu, J. and Wang, W. (2025) Significant Association between Systemic Inflammation Response Index and Prognosis in Patients with Urological Malignancies. Frontiers in Immunology, 16, Article 1518647. [Google Scholar] [CrossRef] [PubMed]
[6] Zhong, W., Chen, H., Yang, J., Huang, C., Lin, Y. and Huang, J. (2023) Inflammatory Response-Based Prognostication and Personalized Therapy Decisions in Clear Cell Renal Cell Cancer to Aid Precision Oncology. BMC Medical Genomics, 16, Article No. 265. [Google Scholar] [CrossRef] [PubMed]
[7] Guo, T., Wang, T., Zhang, J., Chen, S. and Wang, X. (2022) HIF1A Predicts the Efficacy of Anti-Pd-1 Therapy in Advanced Clear Cell Renal Cell Carcinoma. Translational Oncology, 26, Article ID: 101554. [Google Scholar] [CrossRef] [PubMed]
[8] Roussel, E., Kinget, L., Verbiest, A., Debruyne, P.R., Baldewijns, M., Van Poppel, H., et al. (2021) C-Reactive Protein and Neutrophil-Lymphocyte Ratio Are Prognostic in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Nivolumab. Urologic Oncology: Seminars and Original Investigations, 39, 239.e17-239.e25. [Google Scholar] [CrossRef] [PubMed]
[9] Zhang, Y., Shi, C., Chen, Y., Wang, H., Chen, F. and Han, P. (2022) Systematic Analysis of Immune Infiltration and Predicting Prognosis in Clear Cell Renal Cell Carcinoma Based on the Inflammation Signature. Genes, 13, Article 1897. [Google Scholar] [CrossRef] [PubMed]
[10] Labbate, C., Hatogai, K., Werntz, R., Stadler, W.M., Steinberg, G.D., Eggener, S., et al. (2019) Complete Response of Renal Cell Carcinoma Vena Cava Tumor Thrombus to Neoadjuvant Immunotherapy. Journal for ImmunoTherapy of Cancer, 7, Article No. 66. [Google Scholar] [CrossRef] [PubMed]
[11] Kruk, L., Mamtimin, M., Braun, A., Anders, H., Andrassy, J., Gudermann, T., et al. (2023) Inflammatory Networks in Renal Cell Carcinoma. Cancers, 15, Article 2212. [Google Scholar] [CrossRef] [PubMed]
[12] Liu, Y., Yan, W., Tohme, S., Chen, M., Fu, Y., Tian, D., et al. (2015) Hypoxia Induced HMGB1 and Mitochondrial DNA Interactions Mediate Tumor Growth in Hepatocellular Carcinoma through Toll-Like Receptor 9. Journal of Hepatology, 63, 114-121. [Google Scholar] [CrossRef] [PubMed]
[13] Jin, J., Lin, J., Xu, A., Lou, J., Qian, C., Li, X., et al. (2021) CCL2: An Important Mediator between Tumor Cells and Host Cells in Tumor Microenvironment. Frontiers in Oncology, 11, Article 722916. [Google Scholar] [CrossRef] [PubMed]
[14] Xu, W., Wu, Y., Liu, W., Anwaier, A., Tian, X., Su, J., et al. (2022) Tumor-Associated Macrophage-Derived Chemokine CCL5 Facilitates the Progression and Immunosuppressive Tumor Microenvironment of Clear Cell Renal Cell Carcinoma. International Journal of Biological Sciences, 18, 4884-4900. [Google Scholar] [CrossRef] [PubMed]
[15] Gu, X., Tian, T., Tian, X. and Zhang, X. (2015) Prognostic Significance of Neutrophil-To-Lymphocyte Ratio in Non-Small Cell Lung Cancer: A Meta-Analysis. Scientific Reports, 5, Article No. 12493. [Google Scholar] [CrossRef] [PubMed]
[16] Koi, M. and Carethers, J.M. (2017) The Colorectal Cancer Immune Microenvironment and Approach to Immunotherapies. Future Oncology, 13, 1633-1647. [Google Scholar] [CrossRef] [PubMed]
[17] Watnick, R.S. (2012) The Role of the Tumor Microenvironment in Regulating Angiogenesis. Cold Spring Harbor Perspectives in Medicine, 2, a006676. [Google Scholar] [CrossRef] [PubMed]
[18] Boutilier, A.J. and Elsawa, S.F. (2021) Macrophage Polarization States in the Tumor Microenvironment. International Journal of Molecular Sciences, 22, Article 6995. [Google Scholar] [CrossRef] [PubMed]
[19] Wei, Y., Jiang, Y. and Qian, W. (2014) Prognostic Role of NLR in Urinary Cancers: A Meta-Analysis. PLOS ONE, 9, e92079. [Google Scholar] [CrossRef] [PubMed]
[20] Wang, X., Su, S. and Guo, Y. (2017) The Clinical Use of the Platelet to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio as Prognostic Factors in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Oncotarget, 8, 84506-84514. [Google Scholar] [CrossRef] [PubMed]
[21] 马迎光, 孟玮, 刘永烁. LMR对实体肿瘤预后评估作用的研究进展[J]. 医学综述, 2018, 24(3): 481-486.
[22] Arı, E., Köseoğlu, H. and Eroğlu, T. (2024) Predictive Value of SIRI and SII for Metastases in RCC: A Prospective Clinical Study. BMC Urology, 24, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[23] Chen, Z., Wang, K., Lu, H., Xue, D., Fan, M., Zhuang, Q., et al. (2019) Systemic Inflammation Response Index Predicts Prognosis in Patients with Clear Cell Renal Cell Carcinoma: A Propensity Score-Matched Analysis. Cancer Management and Research, 11, 909-919. [Google Scholar] [CrossRef] [PubMed]
[24] Rezazadeh, M., Kamyabi, A., Pisheh, R.G., Noroozie, S., Amiri, B.S., Negahi, A., et al. (2025) Diagnostic Value of Peripheral Blood Inflammatory Indices for Clinicopathological Profile of Colorectal Cancer: A Retrospective Observational Study. BMC Gastroenterology, 25, Article No. 127. [Google Scholar] [CrossRef] [PubMed]
[25] Chen, P., Cheng, L., Zhao, C., Tang, Z., Wang, H., Shi, J., et al. (2024) Machine Learning Identifies Immune-Based Biomarkers That Predict Efficacy of Anti-Angiogenesis-Based Therapies in Advanced Lung Cancer. International Immunopharmacology, 143, Article ID: 113588. [Google Scholar] [CrossRef] [PubMed]
[26] 朱梦柳, 陈力, 孔祥溢, 等. 全身炎症反应指数(SIRI)在乳腺癌患者中的临床意义和预后价值[J]. 现代肿瘤医学, 2022, 30(3): 442-450.
[27] 董杰. 全身炎症反应指数对乳腺癌患者新辅助化疗疗效的预测价值研究[D]: [硕士学位论文]. 合肥: 安徽医科大学, 2022.
[28] Tang, C., Zhang, M., Jia, H., Wang, T., Wu, H., Xu, K., et al. (2024) The Systemic Inflammation Response Index (SIRI) Predicts Survival in Advanced Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy and the Construction of a Nomogram Model. Frontiers in Immunology, 15, Article 1516737. [Google Scholar] [CrossRef] [PubMed]
[29] Brighi, N., Farolfi, A., Conteduca, V., Gurioli, G., Gargiulo, S., Gallà, V., et al. (2019) The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. Cancers, 11, Article 1935. [Google Scholar] [CrossRef] [PubMed]
[30] Rebuzzi, S.E., Buti, S., Galli, L., Procopio, G., De Giorgi, U., Baldessari, C., et al. (2020) Baseline and Early Change of Neutrophil to Lymphocyte Ratio (bNLR and δNLR) as Prognostic Factors in Metastatic Renal Cell Carcinoma (mRCC) Patients Treated with Nivolumab: Preliminary Results of the Meet-Uro 15 (I-BIO-REC) Study. Journal of Clinical Oncology, 38, 752-752. [Google Scholar] [CrossRef] 
[31] Zhao, M., Duan, X., Mi, L., Shi, J., Li, N., Yin, X., et al. (2022) Prognosis of Hepatocellular Carcinoma and Its Association with Immune Cells Using Systemic Inflammatory Response Index. Future Oncology, 18, 2269-2288. [Google Scholar] [CrossRef] [PubMed]
[32] Templeton, A.J., Amir, E., Aneja, P., Vera-Badillo, F.E., Hermanns, T., McNamara, M.G., et al. (2014) Neutrophil to Lymphocyte Ratio and Response to Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 32, 477-477. [Google Scholar] [CrossRef] 
[33] Barata, P.C. and Rini, B.I. (2017) Treatment of Renal Cell Carcinoma: Current Status and Future Directions. CA: A Cancer Journal for Clinicians, 67, 507-524. [Google Scholar] [CrossRef] [PubMed]
[34] Kato, T., Nagahara, A., Kawamura, N., Nakata, W., Soda, T., Matsuzaki, K., et al. (2021) The Prognostic Impact of Immune-Related Adverse Events in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab: A Real-World Multi-Institutional Retrospective Study. International Journal of Clinical Oncology, 26, 954-961. [Google Scholar] [CrossRef] [PubMed]
[35] Ye, K., Xiao, M., Li, Z., He, K., Wang, J., Zhu, L., et al. (2022) Preoperative Systemic Inflammation Response Index Is an Independent Prognostic Marker for BCG Immunotherapy in Patients with Non‐Muscle‐Invasive Bladder Cancer. Cancer Medicine, 12, 4206-4217. [Google Scholar] [CrossRef] [PubMed]
[36] Mao, C., Xu, W., Ma, W., Wang, C., Guo, Z. and Yan, J. (2021) Prognostic Value of Pretreatment Prognostic Nutritional Index in Patients with Renal Cell Carcinoma: A Meta-Analysis. Frontiers in Oncology, 11, Article 719941. [Google Scholar] [CrossRef] [PubMed]
[37] Liu, G., Xiong, D., Che, Z., Chen, H. and Jin, W. (2022) A Novel Inflammation-Associated Prognostic Signature for Clear Cell Renal Cell Carcinoma. Oncology Letters, 24, Article No. 307. [Google Scholar] [CrossRef] [PubMed]
[38] Chen, Y., Xu, T., Jiang, C., You, S., Cheng, Z. and Gong, J. (2022) CT-Based Radiomics Signature to Predict CD8+ Tumor Infiltrating Lymphocytes in Non-Small-Cell Lung Cancer. Acta Radiologica, 64, 1390-1399. [Google Scholar] [CrossRef] [PubMed]
[39] Frankowska, K., Zarobkiewicz, M., Dąbrowska, I. and Bojarska-Junak, A. (2023) Tumor Infiltrating Lymphocytes and Radiological Picture of the Tumor. Medical Oncology, 40, Article No. 176. [Google Scholar] [CrossRef] [PubMed]
[40] Fang, Y., Wang, Y., Yang, L., Yuan, S., Gu, J., Zhou, Z., et al. (2025) Inflammatory Pathways and Immune Microenvironment in Non‐Small Cell Lung Cancer: Multi‐Dimensional Analysis and Machine Learning Prediction. Journal of Cellular and Molecular Medicine, 29, e70689. [Google Scholar] [CrossRef] [PubMed]

为你推荐